Germany was the leading pharmaceutical market in Europe with a total revenue of nearly 69 billion euros in 2023. France and Italy followed with revenues of 46.5 billion and 40.7 billion euros respectively. The top five were rounded off by Spain and Poland. German pharmaceutical marketWhen the revenue of the German pharmacy market is broken down, it is prescription drugs that account for the majority of the revenues. Prescription medication accounted for around 39 billion euros of revenue, followed by pharmacy-only drugs at some 3.5 billion euros. German pharmaceutical exportsOver a 13-year period, the value of pharmaceutical exports from Germany has skyrocketed. Increasing from approximately 18.8 billion euros in 2000 to some 113 billion euros in 2023. The leading destination for these exports is the United States, followed by the Netherlands and Switzerland.

This statistic displays the pharmaceutical industry's market value in Europe by selected countries in 2023. The pharmaceutical market in Denmark was valued at around **** billion euros in that year. Germany was the top-ranked pharmaceutical market in Europe during that year, with a value of over ** billion euros.

Europe Pharmaceutical Drugs Market estimated to grow at a CAGR of 4.5%.

This statistic depicts the European pharmaceutical industry's employment by selected countries in 2023 (or latest year available). The pharmaceutical industry in Denmark employed over 45 thousand persons in that year. Thus, Denmark was ranked among the leading third of countries, based on pharmaceutical employees.

The Europe Pharmaceutical Logistics Market Report is Segmented by Service Type (Transportation, Warehousing & Storage, Value-Added Services), Mode of Operation (Cold-Chain Logistics, Non-Cold-Chain Logistics), Product Type (Prescription Drugs, OTC Drugs, Biologics & Biosimilars, Vaccines & Blood Products, and More), and Geography (Germany, United Kingdom, and More). The Market Forecasts are Provided in Terms of Value (USD).

The Europe Pharmaceutical Market size was valued at USD 296.30 billion in 2023 and is projected to reach USD 428.17 billion by 2032, exhibiting a CAGR of 5.4 % during the forecasts period. Europe Pharmaceutical Market relates to the study, production, manufacturing, and marketing of drugs over the European countries. This market has an important significance in enhancing the standards of human health as it supplies different diseases medications that may be of chronic or temporary nature. Uses include chemotherapy, antibiotics, anti-inflammatory, and other manufactured drugs, as well as household and goggle drugs. Key factors influencing this growth are: shift towards the precision medicine, a significant growth of the biologics and biosimilars market, and innovations in the field of drug delivery systems. Besides, the increasing incidence of chronic diseases, the increase in the geriatric population, and upsurge in the healthcare costs are other factors that fathom this market. The other two factors that are affecting the current environment of European pharmaceutical industries include regulatory dynamics and drive to innovate and come up with new drugs.

The Europe Pharmaceutical Contract Manufacturing Market Report is Segmented by Service Type (API Manufacturing, FDF Development and Manufacturing, and Secondary Packaging), Molecule Type (Small Molecule, and More), Therapeutic Area (Oncology, Cardiovascular, and More), Development Phase (Pre-Clinical, and More), End-Client Type (Big Pharma, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

The European pharmaceutical warehousing market, valued at €24.75 billion in 2025, is experiencing robust growth, projected to expand at a Compound Annual Growth Rate (CAGR) exceeding 8.26% from 2025 to 2033. This expansion is fueled by several key factors. The increasing demand for temperature-sensitive pharmaceutical products, driven by advancements in biotechnology and the rise of specialized medications, necessitates sophisticated cold chain warehousing solutions. Stringent regulatory requirements regarding drug storage and handling further contribute to market growth, pushing pharmaceutical companies to invest in compliant warehousing infrastructure. Furthermore, the growing e-commerce sector in pharmaceuticals is increasing the need for efficient and reliable delivery networks, boosting the demand for pharmaceutical warehousing services. The market is segmented by warehouse type (cold chain and non-cold chain) and application (pharmaceutical factories, pharmacies, hospitals, and others). Germany, the UK, and France represent significant market shares within Europe, reflecting their established pharmaceutical industries and robust healthcare systems. However, emerging markets within the "Rest of Europe" region also offer significant growth potential. The competitive landscape includes major players such as DB Schenker, UPS, and FedEx, alongside specialized pharmaceutical logistics providers. These companies are strategically investing in technological advancements, such as automation and real-time tracking, to enhance efficiency and meet the evolving demands of the pharmaceutical industry. The projected growth trajectory indicates a substantial market expansion over the forecast period. Continuous innovation in cold chain technologies, coupled with increasing investment in infrastructure to meet regulatory compliance, will be primary drivers. While potential restraints could include economic fluctuations and geopolitical uncertainties, the overall market outlook remains positive, driven by the fundamental need for secure and efficient pharmaceutical storage and distribution across Europe. The increasing focus on patient safety and product integrity underscores the long-term viability and growth potential of the European pharmaceutical warehousing market. The presence of established logistics players, coupled with the emergence of specialized niche providers, ensures a dynamic and competitive landscape poised for continued expansion. Recent developments include: June 2023: ViaPharma signed a 20-year lease agreement with the developer CTP for two Czech CTParks. CTP will prepare and hand over the premises, with a total area of almost 27,000 sq m and several specific modifications for the pharmaceutical industry, at the end of 2023. CTPark Ostrava Poruba and CTPark Brno Líšeň will be the next locations of cooperation. ViaPharma already leased three warehouses in Romania, including the largest ever pharmaceutical warehouse in the country with an area of 35,000 sq m in CTPark Mogosoaia., August 2022: UPS announced the acquisition of a top healthcare logistics provider in Italy, BomiGroup. This acquisition was expected to invoke the addition of temperature-controlled facilities in 14 countries.. Key drivers for this market are: The rise in demand for outsourcing pharmaceutical warehousing services, The demand for efficiency, visibility, and product safety from pharmaceutical companies. Potential restraints include: Lack of efficient logistics support in emerging economies. Notable trends are: Rise in the demand Pharmaceutical.

This statistic displays the share of generics in the pharmaceutical market sales value in Europe by selected countries in 2023, including also biosimilars. The generic share in the pharmaceutical industry's market sales in Denmark stood at nearly 40 percent. The market share of generics is higher in newer EU member states due to lower levels of intellectual property protection.

The European pharmaceutical contract manufacturing (PCM) market, valued at €43.02 billion in 2025, is projected to experience robust growth, driven by several key factors. The increasing complexity of drug development and manufacturing processes, coupled with rising R&D expenditures by pharmaceutical companies, is leading to greater outsourcing of manufacturing activities. This trend is particularly pronounced within the European Union, where stringent regulatory requirements and the need to ensure high-quality standards push pharmaceutical firms to leverage the expertise of specialized contract manufacturers. Furthermore, the growing demand for personalized medicines and advanced therapies, such as biologics and cell therapies, is creating new opportunities for PCM providers, stimulating further market expansion. The market is segmented by service type, encompassing active pharmaceutical ingredient (API) manufacturing, finished dosage forms (solid, liquid, and injectable), and secondary packaging. Key players like Fareva Holdings SA, Recipharm AB, and Boehringer Ingelheim Group are actively shaping the market landscape through strategic partnerships, capacity expansions, and technological advancements. The robust pipeline of innovative drug candidates across various therapeutic areas is expected to sustain the market's growth trajectory. The European region's PCM market exhibits strong growth potential across its diverse national markets. Countries like the United Kingdom, Germany, France, and Italy represent significant market segments, driven by their established pharmaceutical industries and robust regulatory frameworks. However, the market is not without its challenges. Fluctuations in raw material prices, intense competition among contract manufacturers, and potential supply chain disruptions pose risks to market growth. Despite these headwinds, the long-term outlook for the European PCM market remains positive, with the projected Compound Annual Growth Rate (CAGR) of 5.01% from 2025 to 2033 signifying substantial expansion. This growth will likely be fueled by sustained investments in advanced manufacturing technologies, increasing demand for specialized services, and a focus on enhancing manufacturing efficiency and sustainability. Recent developments include: May 2024: AGC Biologics, a leading global biopharmaceutical CDMO, partnered with BioConnection, a specialized CMO, to focus on the aseptic filling of vials and syringes for clinical and commercial production.April 2024: Kühne Holding AG entered into a definitive agreement to acquire pharma contract development and manufacturing organization Aenova Group from leading international investment firm BC Partners.. Key drivers for this market are: Increasing Outsourcing Volume by Pharmaceutical Companies, Increasing Investment in R&D. Potential restraints include: Increasing Outsourcing Volume by Pharmaceutical Companies, Increasing Investment in R&D. Notable trends are: The Active Pharmaceutical Ingredient (API) Segment Holds a Major Share in the Market.

This statistic displays the European pharmaceutical industry's production by selected countries in 2023 (or latest year available). The pharmaceutical industry in Switzerland produced pharmaceutical products worth an estimated **** billion euros in 2023.

The European pharmaceutical glass vials and ampoules market, valued at €800 million in 2025, is projected to experience robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 5.42% from 2025 to 2033. This expansion is driven by several key factors. The increasing prevalence of injectable drugs across therapeutic areas, particularly in oncology and biologics, fuels significant demand for primary packaging solutions like vials and ampoules. Furthermore, stringent regulatory requirements regarding drug safety and sterility are pushing manufacturers towards higher-quality, premium glass packaging, contributing to market growth. Growing investments in research and development within the pharmaceutical sector, coupled with the expansion of contract manufacturing organizations (CMOs), further bolster market expansion. The market is segmented geographically, with Germany, Italy, France, the United Kingdom, and Spain representing key contributors, reflecting the concentration of pharmaceutical manufacturing and research activities within these nations. Competition in the market is intense, with established players like Gerresheimer AG, Stevanato Group, and SGD SA vying for market share alongside smaller, specialized manufacturers. The market's trajectory suggests a continued focus on innovation, with ongoing efforts towards developing sustainable and cost-effective packaging solutions. The geographical segmentation within Europe presents diverse market dynamics. While Germany, the UK, and France are expected to maintain significant market share due to their established pharmaceutical industries and robust regulatory frameworks, Italy and Spain present opportunities for growth as their pharmaceutical sectors continue to expand and attract investment. The competitive landscape is characterized by a blend of large multinational corporations and specialized regional players. Large corporations benefit from economies of scale and global distribution networks, while smaller companies focus on niche markets and customized solutions. Future growth will be influenced by factors such as technological advancements in glass manufacturing, the adoption of sustainable packaging practices, and evolving regulatory landscapes. The market is anticipated to see continuous investment in automation and advanced manufacturing techniques to enhance efficiency and product quality. This in-depth report provides a comprehensive analysis of the European pharmaceutical glass vials and ampoules market, offering invaluable insights for stakeholders across the pharmaceutical packaging industry. Utilizing data from the historical period (2019-2024), base year (2025), and forecast period (2025-2033), this report delves into market dynamics, key players, and future growth prospects. With a focus on key European markets including Germany, France, Italy, the United Kingdom, and Spain, this report is essential for strategic decision-making. Recent developments include: May 2024: Gerresheimer Glas GmbH, an indirect subsidiary of Gerresheimer AG, inked a purchase agreement with funds advised by Triton ("Triton") to acquire Blitz LuxCo Sarl, the holding entity of the Bormioli Pharma Group ("Bormioli Pharma"). The agreed purchase price hinges on an enterprise value pegged at approximately EUR 800 million (USD 883.24 million). Bormioli Pharma's diverse portfolio encompasses pharmaceutical primary packaging crafted from both glass and plastic, alongside closure solutions, accessories, and dispensing systems. Through this acquisition, Gerresheimer bolsters its presence in Europe, particularly in Southern regions, and solidifies its stature as a premier full-service provider and global ally to the pharmaceutical and biotech sectors.January 2024: SGD Pharma boosted capacity for siliconized glass vials with a new line. The company inaugurated a new siliconisation operation at its Saint-Quentin Lamotte (SQLM) facility in France. By bringing glass silicification in-house, the company bolsters its already comprehensive suite of services, ensuring quicker responses, a secure supply chain, and greater flexibility in vial sizes. The newly established operation at SQLM can handle all glass types, accommodating vial sizes from 3 ml to 500 ml in both clear and amber variants, all while maintaining a high processing capacity. This treatment caters to diverse market needs, including applications in anti-infectives, parenteral nutrition, diagnostics, animal health, and oncology.. Key drivers for this market are: Investments in Pharmaceutical Industry in the Region, The rising Trend of Sustainable Packaging Significant Growth Opportunities. Potential restraints include: Investments in Pharmaceutical Industry in the Region, The rising Trend of Sustainable Packaging Significant Growth Opportunities. Notable trends are: Ampoules Are Set To Hold Significant Market Share.

This statistic describes the global pharmaceutical sales in from 2020 to 2024, sorted by regional submarkets. For 2024, total pharmaceutical sales in the United States was estimated to reach around *** billion U.S. dollars. World pharmaceutical sales by regionThe pharmaceutical industry is best known for manufacturing pharmaceutical drugs which aim to diagnose, cure, treat, or prevent diseases. The pharmaceutical sector represents a huge industry, with the global market being worth around *** trillion U.S. dollars. Among the best known top global pharmaceutical companies are Pfizer, Merck and Johnson & Johnson from the U.S., Novartis and Roche from Switzerland, Sanofi from France, etc. Accordingly, North America and Europe are still among the largest global submarkets for pharmaceuticals. In 2024, the United States was still the largest single pharmaceutical market, generating more than *** billion U.S. dollars of revenue. Europe was responsible for generating around *** billion U.S. dollars. These two markets, together with Japan, Canada and Australia, form the so-called established (or developed) markets. The rest of the global pharmaceutical revenue is mainly from emerging markets, which include countries like China, Russia, Brazil and India. In fact, these emerging markets show the fastest increase in pharmaceutical sales. Latin America is the world region with the highest predicted compound annual growth rate until 2028.

The Europe Pharmaceutical Cold Chain Logistics Market Report is Segmented by Services (Transportation, Warehousing and Distribution, and More), Temperature Type (Chilled, Frozen, Ambient, and More), Product (Generic Drugs, Branded Drugs, and More), End User (Pharmaceutical Manufacturers, Biotech & Biosimilar Manufacturers, and More), Country (Germany, France, and More). The Market Forecasts are Provided in Terms of Value (USD).

Europe Pharmaceutical Contract Development and Manufacturing Market by Service {Manufacturing [API, FDF (Parenteral, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing, Packaging}, End User [Large Pharma, Generic] - Forecast to 2032

The global pharmaceutical market size is projected to increase from USD 1.74 billion in 2025 to USD 3.21 billion by 2035, with CAGR growth above 6.3%. Notable companies driving the industry include Merck & Co, Novo Nordisk, Pfizer, Eli Lilly, AbbVie, playing a pivotal role in market growth.

Swiss companies Roche and Novartis held the first and third place among European pharma and biotech companies, accumulating a market capitalization of approximately *** and *** billion U.S. dollars, respectively. This statistic shows the leading pharmaceutical and biotechnology companies from Europe as of June 2025, based on market capitalization.

The Italy pharmaceutical market size is projected to exhibit a growth rate (CAGR) of 4.04% during 2025-2033. Italy is among the top pharmaceutical producers in Europe. The market is characterized by robust R&D investments, a growing generic drugs sector, and increasing adoption of digital health technologies. An aging population drives the demand for healthcare, while Italy's strong export capabilities and emphasis on sustainability shape its role as a key player in the European pharmaceutical landscape. These trends further contribute to the market growth of the pharmaceutical industry in Italy.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on type and nature.

Discover the booming 3D printing pharmaceutical market! Explore its $500 million (2025) valuation, 15% CAGR, key drivers (personalized medicine, mass production), restraints, and leading companies. Get insights into regional market share and future projections to 2033.

European Union - Producer prices in industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations was 104.60 points in September of 2025, according to the EUROSTAT. Trading Economics provides the current actual value, an historical data chart and related indicators for European Union - Producer prices in industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations - last updated from the EUROSTAT on December of 2025. Historically, European Union - Producer prices in industry: Manufacture of basic pharmaceutical products and pharmaceutical preparations reached a record high of 111.10 points in February of 2002 and a record low of 98.70 points in June of 2014.